NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage developer of antiviral drugs, has announced that its Phase II clinical trial evaluating NV-387 Oral Gummies for the treatment of Bundibugyo ebolavirus and other Ebola viruses has been officially registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077. The trial will be conducted in the Democratic Republic of Congo (DRC), where the company has already received local regulatory approval from ACOREP to begin the study.
According to the company, NV-387 has been delivered to the clinical trial site in Ituri province, with first patient dosing anticipated within one to two weeks, barring any outbreak-related impediments. The adaptive trial design will commence with a single-arm safety and dose run-in phase before progressing to a randomized, controlled, open-label efficacy evaluation.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features required by viruses for infection. This mechanism is intended to interfere with viral entry and replication across multiple viral families. The drug is also currently being evaluated in a separate Phase II clinical trial for Mpox in the DRC, highlighting its potential versatility in addressing emerging viral threats.
The registration of this trial is a critical milestone for NanoViricides as it advances its lead drug candidate into human trials for Ebola, a disease with high mortality rates and limited treatment options. The DRC has experienced multiple Ebola outbreaks in recent years, and the availability of an oral therapeutic could significantly improve outbreak management, especially in remote areas where intravenous treatments are challenging to administer.
For business and technology leaders, this development underscores the growing role of innovative antiviral platforms in pandemic preparedness and response. The ability to develop broad-spectrum antivirals that can be deployed quickly against various viral pathogens is of strategic importance, not only for public health but also for biosecurity and economic stability. The success of such trials could pave the way for new classes of drugs that reduce the burden on healthcare systems and mitigate the societal disruption caused by viral outbreaks.
NanoViricides' platform technology is based on nanomedicine, utilizing special purpose nanomaterials to create antiviral therapies. The company holds exclusive licenses to this technology for several viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, and Ebola/Marburg viruses, among others. Its business model relies on licensing technology from TheraCour Pharma, Inc., for specific application verticals.
The company's lead drug candidate, NV-387, is being developed for a range of respiratory viral infections, including RSV, COVID-19, Long COVID, and Influenza, as well as Mpox and Measles. Another advanced candidate, NV-HHV-1, targets Shingles. The company has also developed NV-CoV-2, a COVID-19 candidate that does not encapsulate remdesivir, and NV-CoV-2-R, which encapsulates remdesivir within its polymeric micelles.
The Phase II Ebola trial registration is a positive signal for the company's progress, but as with any drug development, there are no guarantees of success. The path to regulatory approval is lengthy and requires substantial capital. However, the potential impact of an effective oral Ebola treatment cannot be overstated, as it could revolutionize outbreak response and save countless lives in affected regions.
For more information on NanoViricides and its pipeline, visit the company's newsroom at https://nnw.fm/NNVC.
